Additionally, patients with glioma with higher C1qtnf6 expression demonstrated higher TIDE scores, suggesting a potentially beneficial response to immune checkpoint blockade (ICB) treatment (Figure 8G). This evidence concerns the gene C1QTNF6 and central nervous system cancer.